Clinical Trials
49 trialsFRONTIER
Miltenyi Biomedicine GmbH
DALY PED
Miltenyi Biomedicine GmbH
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
ImmunityBio, Inc.
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Eli Lilly and Company
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Takeda
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
ImmunityBio, Inc.
SOUNDTRACK-B
AstraZeneca
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Eli Lilly and Company
TRANSCEND FL
Celgene
ELM-2
Regeneron Pharmaceuticals
FIRCE-1
CARGO Therapeutics
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
Cothera Bioscience, Inc
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
CAPITAL
AstraZeneca
ZUMA-12
Gilead Sciences
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
BIANCA
Novartis
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Debiopharm International SA
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Juno Therapeutics, a Subsidiary of Celgene
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
Sierra Oncology LLC - a GSK company
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Eisai Inc.
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Hrain Biotechnology Co., Ltd.
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Spectrum Pharmaceuticals, Inc
SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
PILLAR-1
Novartis
SIGNATURE
Novartis
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
Genor Biopharma Co., Ltd.
A Study for Patients With Non-Hodgkin's Lymphomas
Eli Lilly and Company
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Pharmacyclics LLC.
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Seagen Inc.
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Pharmacyclics LLC.
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Seagen Inc.
A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Genentech, Inc.
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Pfizer
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
Merck Sharp & Dohme LLC
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pharmacyclics LLC.
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Seagen Inc.
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
Astellas Pharma Inc
A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
Sinocelltech Ltd.
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
Bayer
Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma
Transgene
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Telik
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
Eisai Inc.
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
Eisai Inc.
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Millennium Pharmaceuticals, Inc.